. 1998 Jul;72(7):5927–5936. doi: 10.1128/jvi.72.7.5927-5936.1998

TABLE 1.

Drug susceptibilities of recombinant HCMVs expressing various mutations in the UL54 gene

Region	UL54 alteration	Reference(s)^b	Selection drug(s)^c	Fold change in IC₅₀ relative to that for the wild-type recombinant^a
Region	UL54 alteration	Reference(s)^b	Selection drug(s)^c	GCV	CDV	PFA	ADV	LBV
IV	N408D	44	GCV, PFA	4.9	5.6	1.3	−4.0	1.6
	F412C	13, 44	GCV, PFA	4.2	18.0	1.2	−4.2	1.2
	F412V^d	36	GCV	4.3	15.5	1.1	−4.2	1.0
δ C	L501I^d	36	GCV	6.0	9.1	1.4	−2.0	1.4
	K513E	44	GCV, PFA	5.0	9.1	1.4	−2.0	1.2
	P522S	8	GCV, PFA, CDV	3.1	3.6	1.1	−2.5	1.1
	L545S	9	GCV, PFA, CDV	3.5	9.1	1.2	−5.9	1.2
	D588E	44	GCV, PFA	1.3	1.1	2.3	2.0	1.1
II	T700A	2, 4	GCV, PFA	1.2	1.3	5.8	5.8	3.1
	V715M	2, 4	GCV, PFA	1.3	1.1	9.5	6.0	3.1
VI	V781I	2	GCV, PFA	1.0	1.2	5.2	3.0	1.8
III	L802M	13, 44	GCV, PFA	1.1	0.9	3.2	2.8	1.3
	K805Q	44	GCV, PFA	1.0	2.2	−5.6	−4.8	−4.1
	T821I	44	GCV, PFA	4.5	1.9	21	6.4	3.6
V	A987G^d	50	GCV	5.3	11.3	1.2	1.1	1.1
Other	S676G	44	GCV, PFA	1.1	1.2	0.9	1.4	1.0
	V759M	8	CDV	1.5	1.1	1.1	1.2	1.3

Values are averages from at least three determinations with two independently generated recombinant viruses. In all cases, the standard error was less than 35%. Boldface numbers indicate significant (i.e., at least twofold) changes in HCMV drug susceptibility. Positive and negative values represent fold increases and decreases, respectively, in IC₅₀ relative to that of the UL54 wild-type recombinant virus.

Reference(s) describing the original identification of the UL54 alteration.

Therapy after which the mutation in clinical isolate was identified or drug used for selection in cell culture.

UL54 alteration selected in cell culture.